Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Irritable Bowel Syndrome

In brief

This study will explore the safety and effectiveness of different doses of AGN 203818 in relieving Irritable Bowel Syndrome pain. The study is being conducted in 2 parts. Part A enrolled 213 pts dosed with either 3, 20, 60 mg AGN 203818 or placebo over 4 week treatment duration. Part B will enroll 320 pts and dose with either 60, 100, 160 mg BID AGN 203818 or placebo over 12 week treatment duration.

Key facts

Study ID

NCT00441766

Run by

Allergan

People needed

213

Starts

2007-03-01

Expected to finish

2008-02-01

Last updated by the study team

2012-01-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Irritable Bowel Syndrome
• Moderate or severe IBS pain

You may not qualify if…

• Any other uncontrolled disease
• Pregnant or nursing females

Where it is running

• Study site — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.